Everlife

Everlife Asia operates as a pan-regional solutions platform dedicated to enhancing the diagnostic, research, and analytical lab markets across Asia. The company provides a comprehensive suite of clinical diagnostics, analytical solutions, and life science technologies, specifically aimed at improving access to advanced scientific and medical instruments. By building a more efficient value chain, Everlife facilitates the rapid deployment of new technologies across fragmented Asian markets, offering full-service support and custom solutions to its partners.

Established in 2018, Everlife Asia was founded by the private equity firm Everstone Group with the strategic insight to address the critical need for enhanced access to scientific and diagnostic solutions throughout the region. This initiative stemmed from Everstone’s understanding of the fragmented nature of healthcare and research markets, seeking to build a robust platform through strategic acquisitions and organic growth to consolidate and improve the delivery of essential technologies.

Everlife Asia serves healthcare providers, research institutions, and analytical laboratories across seven key Asian markets, with ongoing expansion plans. The company's vision is to advance health and quality of life in Asia by improving accessibility to crucial health technology and science, ultimately enhancing diagnostic, quality, environmental, and safety outcomes for populations throughout the region.